Parkinson’s Disease – Unmet Need – Detailed, Expanded Analysis: Adjunctive Therapies for Motor Fluctuations
Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in early stages of the disease, today’s treatment paradigm is suboptimal owing to considerable pill burden, a risk of motor and nonmotor complications associated with dopaminergic therapy, and a progressive loss of efficacy. In response, the pipeline for therapies targeting motor fluctuations has swelled. With the recent launch of first-in-class A2A receptor antagonist Nourianz, as well as other newer-to-market brands like Xadago and Ongentys, understanding the drivers of clinical decision-making for treating motor fluctuations and prescriber perceptions of approved options will help innovators identify levers for new product positioning and differentiation in this evolving market niche.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for motor fluctuations in PD?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for motor fluctuations in PD?
- What are the prevailing areas of unmet need and opportunity in motor fluctuations in PD?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new motor fluctuations in PD drug?
CONTENT HIGHLIGHTS
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in April and May 2021.
Key companies: UCB, Neurocrine Biosciences / Bial, Newron / Zambon / Supernus, KHK, AbbVie, Cerevel Therapeutics.
Key drugs: Neupro (transdermal rotigotine), Xadago (safinamide), Ongentys (opicapone), Nourianz (istradefylline).
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Table of contents
- Parkinson's Disease - Unmet Need - Detailed, Expanded Analysis: Adjunctive Therapies for Motor Fluctuations
- Unmet Need - Motor Fluctuations in Parkinson's Disease - TPP Simulator - July 2021
- Executive Summary
- Introduction
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Neurologists' Prescribing Decisions for Motor Fluctuations in Parkinson's Disease
- Importance of Efficacy Attributes to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: United States
- Importance of Efficacy Attributes to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: Europe
- Importance of Nonclinical Factors to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: United States
- Importance of Nonclinical Factors to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions for Motor Fluctuations in Parkinson's Disease: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease: United States
- Overall Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease: Europe
- Mean Overall Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease: United States and Europe
- Relative Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need for Motor Fluctuations in Parkinson's Disease
- Surveyed Neurologistsu2019 Satisfaction with the Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Neurologistsu2019 Satisfaction with the Performance of Key Therapies for Motor Fluctuations in Parkinson's Disease on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes for Motor Fluctuations in Parkinson's Disease: United States
- Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes for Motor Fluctuations in Parkinson's Disease: Europe
- Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes for Motor Fluctuations in Parkinson's Disease: United States
- Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes for Motor Fluctuations in Parkinson's Disease: Europe
- Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes for Motor Fluctuations in Parkinson's Disease: United States
- Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes for Motor Fluctuations in Parkinson's Disease: Europe
- Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors for Motor Fluctuations in Parkinson's Disease: United States
- Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors for Motor Fluctuations in Parkinson's Disease: Europe
- Key Findings: Unmet Need for Motor Fluctuations in Parkinson's Disease and Related Indications
- Surveyed Neurologists' Ascribed Level of Unmet Need for Motor Fluctuations in Parkinson's Disease and Related Indications: United States
- Surveyed Neurologists' Ascribed Level of Unmet Need for Motor Fluctuations in Parkinson's Disease and Related Indications: Europe
- Opportunity Analysis
- Target Product Profiles
- Appendix
Joyce Spadafora, A.L.M., is a senior analyst on the CNS/Ophthalmology Disorders team. She authors content on various chronic pain, psychiatric, and neurological indications. Prior to joining the company, she spent several years in the biotech industry focusing on new product development and consulting. She holds a master’s degree in extension studies in psychology from Harvard University and a bachelor’s of science in mechanical engineering with biology from the Massachusetts Institute of Technology.